131 related articles for article (PubMed ID: 1700524)
1. [Myeloid hemopoietic growth factors. Therapeutic possibilities and clinical experiences].
Hansen B; Johnsen HE
Ugeskr Laeger; 1990 Oct; 152(44):3232-7. PubMed ID: 1700524
[TBL] [Abstract][Full Text] [Related]
2. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
3. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
Borota R; Borota J; Belić A; Gebauer E; Stefanović N
Med Pregl; 1997; 50(3-4):87-93. PubMed ID: 9229690
[TBL] [Abstract][Full Text] [Related]
4. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency].
Hansen B; Hippe E; Jacobsen GK; Johnsen HE
Ugeskr Laeger; 1992 Jun; 154(24):1697-702. PubMed ID: 1378668
[TBL] [Abstract][Full Text] [Related]
5. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
Lehrnbecher T
Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
7. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
8. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
[TBL] [Abstract][Full Text] [Related]
9. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
Greenberg PL; Negrin R; Nagler A
Cancer Surv; 1990; 9(1):199-212. PubMed ID: 2276114
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of human granulocyte-macrophage colony-stimulating factor.
Sakamoto KM; Gasson JC
Int J Cell Cloning; 1991 Nov; 9(6):531-41. PubMed ID: 1770227
[TBL] [Abstract][Full Text] [Related]
11. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
12. [Hematopoietic growth factors and anti-infective respiratory defenses].
Gagnadoux F; Diot P; Boissinot E; Lemarié E
Rev Mal Respir; 1997 Apr; 14(2):93-9. PubMed ID: 9198845
[TBL] [Abstract][Full Text] [Related]
13. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
Broxmeyer HE; Cooper S; Williams DE; Hangoc G; Gutterman JU; Vadhan-Raj S
Exp Hematol; 1988 Aug; 16(7):594-602. PubMed ID: 3260558
[TBL] [Abstract][Full Text] [Related]
14. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor.
Broxmeyer HE; Benninger L; Patel SR; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1994 Jan; 22(1):100-2. PubMed ID: 7506671
[TBL] [Abstract][Full Text] [Related]
15. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation.
Barge AJ
Bone Marrow Transplant; 1993; 11 Suppl 2():1-11. PubMed ID: 8334433
[TBL] [Abstract][Full Text] [Related]
16. G-CSF and GM-CSF in clinical trials.
Antman KH
Yale J Biol Med; 1990; 63(5):387-410. PubMed ID: 1705737
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic growth factors in antineoplastic therapy from the therapeutic and economic aspect].
Adam Z; Vorlícek J; Tomíska M
Vnitr Lek; 1993 May; 39(5):487-500. PubMed ID: 7688919
[TBL] [Abstract][Full Text] [Related]
18. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
19. The clinical use of hematopoietic growth factors.
Appelbaum FR
Semin Hematol; 1989 Jul; 26(3 Suppl 3):7-14. PubMed ID: 2477905
[TBL] [Abstract][Full Text] [Related]
20. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
Lemoli RM; Gulati SC
Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
